155 related articles for article (PubMed ID: 10440086)
1. Effects of azimilide, a KV(r) and KV(s) blocker, on canine ventricular arrhythmia models.
Xue Y; Yamada C; Chino D; Hashimoto K
Eur J Pharmacol; 1999 Jul; 376(1-2):27-35. PubMed ID: 10440086
[TBL] [Abstract][Full Text] [Related]
2. Effects of intravenous azimilide on cardiac performance, fibrillation threshold, and hemodynamics in anesthetized dogs.
Brooks RR; Finch SL
Arzneimittelforschung; 2000 Jul; 50(7):597-605. PubMed ID: 10965415
[TBL] [Abstract][Full Text] [Related]
3. Effects of the new class III antiarrhythmic drug MS-551 and d-sotalol on canine coronary ligation-reperfusion ventricular arrhythmias.
Hashimoto K; Haruno A; Hirasawa A; Awaji T; Xue Y; Wu Z
Jpn J Pharmacol; 1995 May; 68(1):1-9. PubMed ID: 7494370
[TBL] [Abstract][Full Text] [Related]
4. Suppression of inducible ventricular arrhythmias by intravenous azimilide in dogs with previous myocardial infarction.
Drexler AP; Micklas JM; Brooks RR
J Cardiovasc Pharmacol; 1996 Dec; 28(6):848-55. PubMed ID: 8961084
[TBL] [Abstract][Full Text] [Related]
5. Azimilide dihydrochloride, a novel antiarrhythmic agent.
Karam R; Marcello S; Brooks RR; Corey AE; Moore A
Am J Cardiol; 1998 Mar; 81(6A):40D-46D. PubMed ID: 9537222
[TBL] [Abstract][Full Text] [Related]
6. The class III effect of azimilide is not associated with reverse use-dependence in open-chest dogs.
Qi XQ; Newman D; Dorian P
J Cardiovasc Pharmacol; 1999 Dec; 34(6):898-903. PubMed ID: 10598136
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of the class III antiarrhythmic agent azimilide in rodent models of ventricular arrhythmia.
Brooks RR; Carpenter JF; Miller KE; Maynard AE
Proc Soc Exp Biol Med; 1996 May; 212(1):84-93. PubMed ID: 8618956
[TBL] [Abstract][Full Text] [Related]
8. Electrophysiological effects of azimilide in an in vitro model of simulated-ischemia and reperfusion in guinea-pig ventricular myocardium.
Ducroq J; Rouet R; Puddu PE; Sallé L; Tabourel C; Ducouret P; Gérard JL
Eur J Pharmacol; 2005 Aug; 518(2-3):165-74. PubMed ID: 16083874
[TBL] [Abstract][Full Text] [Related]
9. Azimilide and dofetilide produce similar electrophysiological and proarrhythmic effects in a canine model of Torsade de Pointes arrhythmias.
Van Opstal JM; Leunissen JD; Wellens HJ; Vos MA
Eur J Pharmacol; 2001 Jan; 412(1):67-76. PubMed ID: 11166738
[TBL] [Abstract][Full Text] [Related]
10. QT-prolonging class I drug, disopyramide, does not aggravate but suppresses adrenaline-induced arrhythmias. Comparison with cibenzoline and pilsicainide.
Miyamoto S; Zhu B; Teramatsu T; Aye NN; Hashimoto K
Eur J Pharmacol; 2000 Jul; 400(2-3):263-9. PubMed ID: 10988343
[TBL] [Abstract][Full Text] [Related]
11. Electrophysiological and antiarrhythmic effects of the novel I(Kur) channel blockers, S9947 and S20951, on left vs. right pig atrium in vivo in comparison with the I(Kr) blockers dofetilide, azimilide, d,l-sotalol and ibutilide.
Knobloch K; Brendel J; Peukert S; Rosenstein B; Busch AE; Wirth KJ
Naunyn Schmiedebergs Arch Pharmacol; 2002 Nov; 366(5):482-7. PubMed ID: 12382079
[TBL] [Abstract][Full Text] [Related]
12. Azimilide decreases defibrillation voltage requirements and increases spatial organization during ventricular fibrillation.
Qi XQ; Newman D; Dorian P
J Interv Card Electrophysiol; 1999 Mar; 3(1):61-7. PubMed ID: 10354978
[TBL] [Abstract][Full Text] [Related]
13. Azimilide (NE-10064) can prolong or shorten the action potential duration in canine ventricular myocytes: dependence on blockade of K, Ca, and Na channels.
Yao JA; Tseng GN
J Cardiovasc Electrophysiol; 1997 Feb; 8(2):184-98. PubMed ID: 9048249
[TBL] [Abstract][Full Text] [Related]
14. Azimilide.
Clemett D; Markham A
Drugs; 2000 Feb; 59(2):271-7; discussion 278-9. PubMed ID: 10730550
[TBL] [Abstract][Full Text] [Related]
15. The azimilide post-infarct survival evaluation (ALIVE) trial.
Camm AJ; Karam R; Pratt CM
Am J Cardiol; 1998 Mar; 81(6A):35D-39D. PubMed ID: 9537221
[TBL] [Abstract][Full Text] [Related]
16. Effects of azimilide dihydrochloride on circus movement atrial flutter in the canine sterile pericarditis model.
Restivo M; Hegazy M; Caref EB; Avitable MJ; Assadi MA; el-Hamami M; Yin H; Piracha M; Brooks RR; el-Sherif N
J Cardiovasc Electrophysiol; 1996 Jul; 7(7):612-24. PubMed ID: 8807407
[TBL] [Abstract][Full Text] [Related]
17. Protection against programmed electrical stimulation-induced ventricular tachycardia and sudden cardiac death by NE-10064, a class III antiarrhythmic drug.
Black SC; Butterfield JL; Lucchesi BR
J Cardiovasc Pharmacol; 1993 Dec; 22(6):810-8. PubMed ID: 7509898
[TBL] [Abstract][Full Text] [Related]
18. Antiarrhythmic properties of a prior oral loading of amiodarone in in vivo canine coronary ligation/reperfusion-induced arrhythmia model: comparison with other class III antiarrhythmic drugs.
Nagasawa Y; Chen J; Hashimoto K
J Pharmacol Sci; 2005 Mar; 97(3):393-9. PubMed ID: 15764841
[TBL] [Abstract][Full Text] [Related]
19. Azimilide. NE 10064, Stedicor.
Drugs R D; 1999 Apr; 1(4):297-300. PubMed ID: 10566048
[No Abstract] [Full Text] [Related]
20. Antiarrhythmic effects of a novel class III drug, KCB-328, on canine ventricular arrhythmia models.
Xue Y; Tanabe S; Nabuchi Y; Hashimoto K
J Cardiovasc Pharmacol; 1998 Aug; 32(2):239-47. PubMed ID: 9700986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
